Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effects of PCSK9 Targeting: Alleviating Oxidation, Inflammation, and Atherosclerosis
Emily Punch, Justus Klein, Patrick Diaba‐Nuhoho, et al.
Journal of the American Heart Association (2022) Vol. 11, Iss. 3
Open Access | Times Cited: 56

Showing 1-25 of 56 citing articles:

Causal relationship between PCSK9 inhibitor and autoimmune diseases: a drug target Mendelian randomization study
Weijia Xie, Jiaxin Li, Hao Du, et al.
Arthritis Research & Therapy (2023) Vol. 25, Iss. 1
Open Access | Times Cited: 37
Targeting inflammation in atherosclerosis: overview, strategy and directions
Ron Waksman, Ilan Merdler, Brian C. Case, et al.
EuroIntervention (2023) Vol. 20, Iss. 1, pp. 32-44
Closed Access | Times Cited: 24
Effects of alirocumab on endothelial function and coronary atherosclerosis in myocardial infarction: A PACMAN-AMI randomized clinical trial substudy
Emrush Rexhaj, Sarah Bär, Rodrigo Soria, et al.
Atherosclerosis (2024) Vol. 392, pp. 117504-117504
Open Access | Times Cited: 9
The role of PCSK9 in heart failure and other cardiovascular diseases—mechanisms of action beyond its effect on LDL cholesterol
Mieczysław Dutka, Karolina Zimmer, Michał Ćwiertnia, et al.
Heart Failure Reviews (2024) Vol. 29, Iss. 5, pp. 917-937
Open Access | Times Cited: 8
Adjunctive PCSK9 Inhibitor Evolocumab in the Prevention of Early Neurological Deterioration in Non-cardiogenic Acute Ischemic Stroke: A Multicenter, Prospective, Randomized, Open-Label, Clinical Trial
Wen Tian, Hua Cao, Xidan Li, et al.
CNS Drugs (2025)
Closed Access | Times Cited: 1
Inclisiran—Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9
Łukasz Wołowiec, Joanna Osiak, Anna Wołowiec, et al.
Pharmaceutics (2023) Vol. 15, Iss. 2, pp. 323-323
Open Access | Times Cited: 18
Regulation of endothelial function by cigarette smoke and next-generation tobacco and nicotine products
Justus Klein, Patrick Diaba‐Nuhoho, Sindy Giebe, et al.
Pflügers Archiv - European Journal of Physiology (2023) Vol. 475, Iss. 7, pp. 835-844
Open Access | Times Cited: 17
Macrophage polarisation and inflammatory mechanisms in atherosclerosis: Implications for prevention and treatment
Bo Yang, Sanhua Hang, Siting Xu, et al.
Heliyon (2024) Vol. 10, Iss. 11, pp. e32073-e32073
Open Access | Times Cited: 6
Association of hydroxytyrosol enriched olive oil with vascular function in chronic coronary disease
Ignatios Ikonomidis, Κ Katogiannis, C Chania, et al.
European Journal of Clinical Investigation (2023) Vol. 53, Iss. 7
Open Access | Times Cited: 15
Association of Circulating PCSK9 With Ischemia-Reperfusion Injury in Acute ST-Elevation Myocardial Infarction
Christina Tiller, Magdalena Holzknecht, Ivan Lechner, et al.
Circulation Cardiovascular Imaging (2024) Vol. 17, Iss. 8
Closed Access | Times Cited: 4
Conditional knockdown of hepatic PCSK9 ameliorates high-fat diet-induced liver inflammation in mice
Xueying Zhang, Qingqing Lu, Yanjie Li, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Early PCSK9 Inhibitor Therapy Following Percutaneous Coronary Intervention (PERFECT): A Pilot Randomized Controlled Trial
Jiachun Xia, Zhengguang Xiao, Luyao Wu, et al.
Cardiology Discovery (2025)
Open Access
The Role of Olive Oil in Cardiometabolic Risk
Andrea Salvo, Antonino Tuttolomondo
Metabolites (2025) Vol. 15, Iss. 3, pp. 190-190
Open Access
PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk
Pere Rehues, Josefa Girona, Montse Guardiola, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2319-2319
Open Access | Times Cited: 12
Treatment with PCSK9 Inhibitor Evolocumab Improves Vascular Oxidative Stress and Arterial Stiffness in Hypercholesterolemic Patients with High Cardiovascular Risk
Alessia Silla, Federica Fogacci, Angela Punzo, et al.
Antioxidants (2023) Vol. 12, Iss. 3, pp. 578-578
Open Access | Times Cited: 11
PCSK9 inhibitor inclisiran for treating atherosclerosis via regulation of endothelial cell pyroptosis
Ni Kong, Qin Xu, Wei Cui, et al.
Annals of Translational Medicine (2022) Vol. 10, Iss. 22, pp. 1205-1205
Open Access | Times Cited: 18
PCSK9 aggravated carotid artery stenosis in ApoE-/- mice by promoting the expression of tissue factors in endothelial cells via the TLR4/NF-κB pathway
Chao Peng, Jian Li, Yan Chen, et al.
Biochemical Pharmacology (2024) Vol. 225, pp. 116314-116314
Closed Access | Times Cited: 3
Role of CETP, PCSK-9, and CYP7-alpha in cholesterol metabolism: Potential targets for natural products in managing hypercholesterolemia
Rita Ngozi Aguchem, Innocent Uzochukwu Okagu, Ekezie Matthew Okorigwe, et al.
Life Sciences (2024) Vol. 351, pp. 122823-122823
Open Access | Times Cited: 3
Early and Short-term Use of PCSK9-Inhibitors on Coronary Plaque Stability in Acute Coronary Syndrome
Hiroki Uehara, Takashi Kajiya, Masami Abe, et al.
European Heart Journal Open (2024) Vol. 4, Iss. 4
Open Access | Times Cited: 3
PCSK9 Confers Inflammatory Properties to Extracellular Vesicles Released by Vascular Smooth Muscle Cells
Maria Francesca Greco, Alessandra Stefania Rizzuto, M Zara, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 21, pp. 13065-13065
Open Access | Times Cited: 15
PCSK9 inhibitor attenuates atherosclerosis by regulating SNHG16/EZH2/TRAF5‐mediated VSMC proliferation, migration, and foam cell formation
Yan Liu, Yueyan Zhao, Panyang Feng, et al.
Cell Biology International (2023) Vol. 47, Iss. 7, pp. 1267-1280
Closed Access | Times Cited: 8
Non-Lipid Effects of PCSK9 Monoclonal Antibodies on Vessel Wall
Sabina Ugovšek, Miran Šebeštjen
Journal of Clinical Medicine (2022) Vol. 11, Iss. 13, pp. 3625-3625
Open Access | Times Cited: 13
Drug Target Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Atrial Fibrillation
Fuyuan Li, Yibin Mei, Qiongbi Wu, et al.
Cardiology (2024) Vol. 149, Iss. 5, pp. 495-501
Open Access | Times Cited: 2
Translocator Protein 18 kDa Tracer 18F-FDPA PET/CTA Imaging for the Evaluation of Inflammation in Vulnerable Plaques
Jian Jiao, Biao Hu, Tiantian Mou, et al.
Molecular Pharmaceutics (2024) Vol. 21, Iss. 7, pp. 3623-3633
Closed Access | Times Cited: 2
PCSK9 in T-cell function and the immune response
Yuying Wang, Xiaosheng Fang, Jiarui Liu, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top